Posted on August 5th, 2015 by msequeira
Angela Wandinger-Ness, PhD, Laurie Hudson, PhD, and Carolyn Muller, MD, led a team at UNM Cancer Center that discovered a previously unknown effect of the pain medicine ketorolac. Ketorolac is marketed as Toradol® and used to relieve pain after surgery. The FDA approved it in the 1970s.
Drs. Wandinger-Ness, Hudson, Muller and their team discovered that a component of the drug acts on GTPases in ovarian cancer cells. GTPases are molecular switches that control cell behavior. The component in ketorolac keeps ovarian cancer cells from growing and spreading.
Read the media alert about their work and view the interviews on "The Morning Brew" with Dan Mayfield and on "KRQE This Morning" with Adam Attchison.
You must be logged-in to the site to post a comment.